Service
-
For Authors
How to submit, copyright, proposals, discount.
-
For Librarians
Ejournals, ebooks, collections, pricing, usage statistics.
-
For Book Reviewers
How to request a book,
terms and conditions.
Our (e)Books and (e)Journals
IOS Press serves the information needs of scientific and medical communities worldwide. See what's new and browse our books and journals to learn more.
Browse by Subject
IOS Press publishes books and journals (online and in print) in a broad range of scientific, technical and medical (STM) subject areas. Click on a subject above to see our titles.
Service
-
For Authors
How to submit, copyright, proposals, discount.
-
For Librarians
Ejournals, ebooks, collections, pricing, usage statistics.
-
For Book Reviewers
How to request a book,
terms and conditions.
News
Keep me informedNew Study Shows a Minimum Dose of Hydromethylthionine Could Slow Cognitive Decline and Brain Atrophy in Mild-to-Moderate Alzheimer’s Disease
November 27, 2019 - Aberdeen, UK and Singapore, Singapore – In a paper published in today's online issue of the Journal of Alzheimer's Disease, TauRx has reported unexpected results of a pharmacokinetic analysis of the relationship between treatment dose, blood levels and pharmacological activity of the drug hydromethylthionine on the brain in over 1,000 patients with mild-to-moderate Alzheimer's disease. These results showed that, even at the lowest dose of hydromethylthionine previously tested in two Phase 3 global clinical trials (8 mg/day), the drug produced concentration-dependent effects on cognitive decline and brain atrophy.
November 27, 2019Psychological Well-Being at 52 Years Could Impact on Cognitive Functioning at 69 Years
November 26, 2019 - Tokyo, Japan – People around the world are living longer, and dementia has consequently become recognized as a public health priority in many countries. The Lancet Commission paper in 2017 collated a large body of medical research evidence that aims to address the dementia epidemic and following challenge for health and social care. It is estimated that as much as 35% of dementia cases could be prevented by targeting nine modifiable risk factors. However, relatively little is known about psychological well-being in this context.
November 26, 2019Oligomerix and Feinstein Institutes Publish In Vivo Alzheimer’s Disease Treatment Data
November 20, 2019 - New York, USA – Oligomerix, Inc., a privately held company pioneering the development of tau oligomer inhibitors for Alzheimer's disease (AD) and related neurodegenerative disorders, and the Feinstein Institutes for Medical Research announced today the publication of preclinical data demonstrating that an oral small molecule drug inhibits the formation of neurotoxic tau oligomers in an animal model of tau aggregation most relevant to AD. The study showed that the compound blocked tau self-association, which is the earliest step in the toxic tau aggregation cascade, and inhibited the downstream events that lead to tau fibril formation.
November 20, 2019Getting to the “Art” of Dementia: UC Researchers Highlight Benefits of Art Intervention
November 14, 2019 - Canberra, Australia – University of Canberra researchers have shown that art gallery programs can improve the wellbeing of people living with dementia – and they’ve backed it up by testing study participants’ saliva. The study is published in the Journal of Alzheimer's Disease, the UC study monitored new participants of the National Gallery of Australia's (NGA) Art and Dementia program over six weeks. The NGA program has been running for more than 12 years and has demonstrated anecdotal and observational benefits, now backed up by UC research.
November 14, 2019